[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$morfs
$MORFS sees increased engagement due to positive discussions around $ABVX clinical trial data. Community is growing as users share insights on trial results.
About $morfs
A topic related to financial markets, likely a stock or cryptocurrency.
Engagements: XXXXX #
Engagements 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XXXXX
1-Year High: XXXXX on 2025-07-22
1-Year Low: XXXXX on 2025-07-23
| Social Network | X |
|---|---|
| Engagements | XXXXX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-23
1-Year Low: X on 2025-07-21
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $morfs in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-07-21
1-Year Low: X on 2025-07-21
Top topics mentioned In the posts about $morfs in the last XX hours
longterm, $abvx, $abvxs, delta, drugs, rates
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Duration of response is definitely key and its another under appreciated point from the P2 datasets that points to $ABVX Obefazimod being highly active imo. Basically the (severe) patients in the ABVX OLEs stayed on the drug at similar or higher rates than patients do on FDA-approved drugs that we know are active. Sounds like drug activity to me"
@A_May_MD on X 2025-07-21 15:38:03 UTC 12.7K followers, 3386 engagements
"Slide 5: $ABVX P2a+P2b Pooled Induction and Long-term OLE Data With Attrition Analysis Before their P2b $ABVX had run a randomized and controlled P2a trial as well (important because many P2a studies like $MORFs are done open label). Unlike the P2b that had an outlier low remission delta $ABVXs P2a clinical remission delta was concordant with the rest of their efficacy data coming in at a very impressive XX% 🗒Note the P2a was a much smaller sample size so the best utility of this dataset is to pool it with the P2b numbers. Combining the P2a sample with the P2b sample raises $ABVXs clinical"
@A_May_MD on X 2025-07-21 13:34:02 UTC 12.7K followers, 8846 engagements